発作性夜間ヘモグロビン尿症（PNH）治療の世界市場レポート 2025年

発作性夜間ヘモグロビン尿症（PNH）治療市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は13.5％で、100億9,000万米ドルに成長します。予測期間に予測される成長は、希少疾患の有病率の上昇、ヘルスケア支出の増加、先進治療へのアクセスの拡大など、いくつかの要因に起因しています。さらに、ヘルスケアインフラへの投資の増加、在宅検査や遠隔モニタリングの増加、研究開発活動の活発化なども挙げられます。この間の主な動向としては、遺伝子検査やバイオマーカーの進歩、治療の進歩、標的治療の開発、バイオテクノロジーの革新、新規治療法の創出などが挙げられます。

血液疾患の有病率の増加は、発作性夜間ヘモグロビン尿症（PNH）治療市場の拡大を牽引すると予想されます。血液疾患には、赤血球、白血球、血小板、骨髄、凝固系の異常など、血液や造血器官に影響を及ぼすさまざまな病態が含まれます。これらの疾患は貧血、凝固障害、悪性腫瘍を引き起こす可能性があります。血液疾患の罹患率の上昇には、人口の高齢化や遺伝的素因などの要因が拍車をかけており、遺伝的変異は血球産生異常の引き金として重要な役割を果たし、様々な血液疾患につながります。PNH治療は、補体を介する溶血に対処し、血栓性合併症を減少させ、患者の生存期間を改善する標的治療を提供することにより、これらの疾患を管理する上で重要な役割を果たしています。例えば、2024年7月、英国を拠点とする慈善団体Cancer Research UKは、英国における新たな白血病患者数は2023-2025年の約1万2,400人から2038-2040年には約1万4,500人に増加すると予想されると報告しました。このような血液疾患の発生率の増加が、PNH治療市場の成長を牽引しています。

PNH治療市場の主要企業は、経口B因子阻害薬などの革新的なソリューションの開発に注力しており、PNHの管理における治療効果と患者の利便性を高める新たな治療オプションを提供しています。経口B因子阻害薬は、代替補体経路のB因子を選択的に阻害する標的低分子薬であり、免疫系の過剰活性化を制御し、補体を介する疾患における炎症を抑制します。例えば、2023年12月、スイスに本社を置く製薬会社ノバルティスAGは、PNHの治療薬として初の経口単剤療法であるファブハルタ（イプタコパン）のFDA承認を発表しました。この新しい第B因子阻害剤は、補体介在性溶血を制御するためのより包括的なアプローチを提供するもので、より早期に補体代替経路を標的とし、ヘモグロビン値を改善し、輸血の必要性を低減します。ファブハルタの承認は、PNH治療における重要な進歩を意味し、より高い有効性、より良い患者コンプライアンス、そしてこの稀な血液疾患の治療状況を一変させる、静脈内治療に代わる実行可能な選択肢を提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界発作性夜間ヘモグロビン尿症（PNH）治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の発作性夜間ヘモグロビン尿症（PNH）治療市場：成長率分析
• 世界の発作性夜間ヘモグロビン尿症（PNH）治療市場の実績：規模と成長, 2019-2024
• 世界の発作性夜間ヘモグロビン尿症（PNH）治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界発作性夜間ヘモグロビン尿症（PNH）治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の発作性夜間ヘモグロビン尿症（PNH）治療市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 補体C5阻害剤
• 抗補体成分5a受容体（C5aR）モノクローナル抗体
• 代替経路阻害剤
• 造血幹細胞移植
• その他の治療法
• 世界の発作性夜間ヘモグロビン尿症（PNH）治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• 皮下
• オーラル
• 世界の発作性夜間ヘモグロビン尿症（PNH）治療市場の入手可能性、実績と予測, 2019-2024, 2024-2029F, 2034F
• 承認
• パイプライン中
• 調査中
• 世界の発作性夜間ヘモグロビン尿症（PNH）治療市場：最終用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 在宅ケア設定
• その他のエンドユーザー
• 世界の発作性夜間ヘモグロビン尿症（PNH）治療市場補体C5阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エクリズマブ（ソリリス）
• ラブリズマブ（ウルトミリス）
• 研究開発（パイプライン医薬品）
• 他の免疫抑制剤との併用療法
• 長期的な有効性と安全性のプロファイル
• 世界の発作性夜間ヘモグロビン尿症（PNH）治療市場抗補体成分5a受容体（C5aR）モノクローナル抗体のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 開発中の医薬品候補
• 作用機序
• 治療領域
• アンカ関連血管炎
• 慢性閉塞性肺疾患（COPD）
• 関節リウマチ
• 全身性エリテマトーデス（SLE）
• 安全性と有害事象
• 有効性と臨床試験の結果
• 開発の将来方向
• 世界の発作性夜間ヘモグロビン尿症（PNH）治療市場代替経路阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• C3阻害剤
• B因子阻害剤
• 因子D阻害剤
• 補体増幅を標的とする
• 併用療法と二重阻害
• 臨床試験における有効性と安全性
• 世界の発作性夜間ヘモグロビン尿症（PNH）治療市場造血幹細胞移植の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自家造血幹細胞移植と同種造血幹細胞移植
• 移植前のコンディショニング療法：
• 移植後の免疫抑制療法
• 幹細胞源
• 適応症
• 合併症
• 最近の進歩
• 世界の発作性夜間ヘモグロビン尿症（PNH）治療市場その他の治療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫抑制療法
• 支持療法
• 抗凝固療法
• 遺伝子治療

第7章 地域別・国別分析

• 世界の発作性夜間ヘモグロビン尿症（PNH）治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の発作性夜間ヘモグロビン尿症（PNH）治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 発作性夜間ヘモグロビン尿症（PNH）治療市場：競合情勢
• 発作性夜間ヘモグロビン尿症（PNH）治療市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Regeneron Pharmaceuticals
• Cleveland Clinic Foundation
• Johns Hopkins Medicine
• Memorial Sloan Kettering Cancer Center
• Stanford Health Care
• University of California San Francisco（UCSF）Health
• Emory Healthcare
• Cedars-Sinai Medical Center
• Duke University Health System
• Mount Sinai Health System
• Dana-Farber Cancer Institute
• Swedish Orphan Biovitrum
• Alnylam Pharmaceuticals
• BioCryst Pharmaceuticals
• Apellis Pharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 発作性夜間ヘモグロビン尿症（PNH）治療市場2029：新たな機会を提供する国
• 発作性夜間ヘモグロビン尿症（PNH）治療市場2029：新たな機会を提供するセグメント
• 発作性夜間ヘモグロビン尿症（PNH）治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Paroxysmal nocturnal hemoglobinuria (PNH) treatment involves medical therapies aimed at managing this rare blood disorder, which is characterized by hemolysis (destruction of red blood cells), blood clots, and bone marrow dysfunction. PNH is an acquired hematologic disorder where red blood cell destruction occurs due to complement-mediated hemolysis, bone marrow dysfunction leading to cytopenias, and an increased risk of thrombosis. The primary focus of PNH management is to inhibit complement activation to prevent hemolysis, address bone marrow failure, and reduce thrombotic complications, ultimately improving patient outcomes and quality of life.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main treatment options for PNH include complement C5 inhibitors, anti-complement component 5a receptor (C5aR) monoclonal antibodies, alternative pathway inhibitors, hematopoietic stem cell transplantation, and others. Complement C5 inhibitors are a class of targeted therapies that block the cleavage of complement component 5 (C5) in the immune system's complement cascade, preventing the formation of membrane attack complexes. This reduces complement-mediated hemolysis and inflammation in PNH and other complement-driven diseases. These therapies are administered through various routes, including intravenous, subcutaneous, and oral. The drugs are available in the market as approved, in the pipeline, and in investigational stages, and are used in settings such as hospitals, specialty clinics, homecare environments, and others.

The paroxysmal nocturnal hemoglobinuria (PNH) treatment market research report is one of a series of new reports from The Business Research Company that provides paroxysmal nocturnal hemoglobinuria (PNH) treatment market statistics, including paroxysmal nocturnal hemoglobinuria (PNH) treatment industry global market size, regional shares, competitors with a paroxysmal nocturnal hemoglobinuria (PNH) treatment market share, detailed paroxysmal nocturnal hemoglobinuria (PNH) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the paroxysmal nocturnal hemoglobinuria (PNH) treatment industry. This paroxysmal nocturnal hemoglobinuria (PNH) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The paroxysmal nocturnal hemoglobinuria (PNH) treatment market size has grown rapidly in recent years. It will grow from $5.35 billion in 2024 to $6.09 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth observed in the historic period can be attributed to several factors, including the high prevalence of neurological disorders and chronic pain conditions, growing awareness of PNH, increasing recognition of rare hematological disorders, and a rise in regulatory approvals. Additionally, there has been a notable increase in research and development (R&D) efforts.

The paroxysmal nocturnal hemoglobinuria (PNH) treatment market size is expected to see rapid growth in the next few years. It will grow to $10.09 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. The growth projected for the forecast period can be attributed to several factors, including the rising prevalence of rare diseases, increased healthcare expenditure, and greater access to advanced therapies. Additionally, there is a growing investment in healthcare infrastructure, a rise in home-based testing and remote monitoring, and an increase in research and development activities. Key trends during this period include advancements in genetic testing and biomarkers, progress in therapies, the development of targeted treatments, innovations in biotechnology, and the creation of novel therapies.

The growing prevalence of hematologic disorders is expected to drive the expansion of the paroxysmal nocturnal hemoglobinuria (PNH) treatment market. Hematologic disorders encompass a wide range of medical conditions that affect the blood and blood-forming organs, including abnormalities in red blood cells, white blood cells, platelets, bone marrow, and the coagulation system. These conditions can lead to anemia, clotting disorders, or malignancies. The rising incidence of hematologic disorders is fueled by factors such as aging populations and genetic predispositions, with genetic mutations playing a crucial role in triggering abnormal blood cell production, leading to various hematologic diseases. PNH treatment plays a key role in managing these disorders by offering targeted therapies that address complement-mediated hemolysis, reduce thrombotic complications, and improve patient survival. For example, in July 2024, Cancer Research UK, a UK-based charity, reported that the number of new leukemia cases in the UK is expected to rise from around 12,400 between 2023-2025 to approximately 14,500 by 2038-2040. This increasing incidence of hematologic disorders is driving growth in the PNH treatment market.

Leading companies in the PNH treatment market are focusing on developing innovative solutions, such as oral Factor B inhibitors, which offer novel treatment options that enhance therapeutic effectiveness and patient convenience in managing PNH. An oral Factor B inhibitor is a targeted small-molecule drug that selectively inhibits Factor B in the alternative complement pathway, regulating immune system overactivation and reducing inflammation in complement-mediated diseases. For instance, in December 2023, Novartis AG, a Switzerland-based pharmaceutical company, announced the FDA approval of Fabhalta (iptacopan) as the first oral monotherapy for the treatment of PNH. This new Factor B inhibitor provides a more comprehensive approach to controlling complement-mediated hemolysis by targeting the alternative complement pathway earlier, improving hemoglobin levels, and reducing the need for blood transfusions. The approval of Fabhalta represents a significant advancement in PNH treatment, offering enhanced efficacy, better patient compliance, and a viable alternative to intravenous therapies, transforming the treatment landscape for this rare hematologic disorder.

In December 2024, The Max Foundation, a US-based nonprofit organization, announced a collaboration with Novartis AG to improve global health equity by expanding access to innovative treatments for underserved populations. This partnership aims to increase access to advanced PNH treatments in low-resource countries by leveraging strategic partnerships, strengthening healthcare infrastructure, providing essential medications at no cost, and fostering medical expertise through education and capacity-building initiatives. The goal is to ensure equitable healthcare access and improve patient outcomes worldwide. Novartis AG, a Switzerland-based pharmaceutical company, developed the oral monotherapy to manage PNH.

Major players in the paroxysmal nocturnal hemoglobinuria (pnh) treatment market are F. Hoffmann-La Roche Ltd, AstraZeneca PLC, Novartis AG, Amgen Inc., Mayo Clinic, Regeneron Pharmaceuticals, Cleveland Clinic Foundation, Johns Hopkins Medicine, Memorial Sloan Kettering Cancer Center, Stanford Health Care, University of California San Francisco (UCSF) Health, Emory Healthcare, Cedars-Sinai Medical Center, Duke University Health System, Mount Sinai Health System, Dana-Farber Cancer Institute, Swedish Orphan Biovitrum, Alnylam Pharmaceuticals, BioCryst Pharmaceuticals, Apellis Pharmaceuticals.

North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in paroxysmal nocturnal hemoglobinuria (PNH) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the paroxysmal nocturnal hemoglobinuria (PNH) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The paroxysmal nocturnal hemoglobinuria (PNH) treatment market includes revenues earned by entities by providing services such as diagnostic testing services, genetic counseling, patient support programs, blood transfusion services, iron supplementation therapy, clinical trial services, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on paroxysmal nocturnal hemoglobinuria (pnh) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for paroxysmal nocturnal hemoglobinuria (pnh) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The paroxysmal nocturnal hemoglobinuria (pnh) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Complement C5 Inhibitors; Anti-Complement Component 5a Receptor (C5aR) Monoclonal Antibodies; Alternative Pathway Inhibitors; Hematopoietic Stem Cell Transplantation; Other Therapies
• 2) By Route Of Administration: Intravenous; Subcutaneous; Oral
• 3) By Market Availability: Approved; In Pipeline; Investigational
• 4) By End-Use: Hospitals; Specialty Clinics; Homecare Settings; Other End-Users
• Subsegments:
• 1) By Complement : C5 InhibitorsEculizumab (Soliris); Ravulizumab (Ultomiris); Emerging C5 Inhibitors; Biosimilars Of C5 Inhibitors,
• 2) By Anti-Complement Component 5a Receptor Monoclonal Antibodies: Avacopan (Tavneos); Other Investigational C5aR mAbs; Monotherapy vs Combination Therapy; Clinical Trial Phase (Phase I, II, III)
• 3) By Alternative Pathway Inhibitors: C3 Inhibitors; Factor B Inhibitors; Factor D Inhibitors; Targeting Complement Amplification; Combination Therapies And Dual Inhibition
• 4) By Hematopoietic Stem Cell Transplantation (HSCT) : Autologous HSCT vs. Allogeneic HSCT; Pre-Transplant Conditioning Therapies; Post-Transplant Immunosuppressive Therapies
• 5) By Other Therapies: Immunosuppressive Therapy; Supportive Care; Anticoagulation Therapy; Gene Therapy
• Companies Mentioned: F. Hoffmann-La Roche Ltd; AstraZeneca PLC; Novartis AG; Amgen Inc.; Mayo Clinic
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Characteristics

3. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Trends And Strategies

4. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Growth Rate Analysis
• 5.4. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Total Addressable Market (TAM)

6. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Segmentation

• 6.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Complement C5 Inhibitors
• Anti-Complement Component 5a Receptor (C5aR) Monoclonal Antibodies
• Alternative Pathway Inhibitors
• Hematopoietic Stem Cell Transplantation
• Other Therapies
• 6.2. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Subcutaneous
• Oral
• 6.3. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Approved
• In Pipeline
• Investigational
• 6.4. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare Settings
• Other End-Users
• 6.5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Sub-Segmentation Of Complement C5 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Eculizumab (Soliris)
• Ravulizumab (Ultomiris)
• Research And Development (Pipeline Drugs)
• Combination Therapies With Other Immunosuppressants
• Long-Term Efficacy And Safety Profiles
• 6.6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Sub-Segmentation Of Anti-Complement Component 5a Receptor (C5aR) Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug Candidates In Development
• Mechanism Of Action
• Therapeutic Areas
• Anca-Associated Vasculitis
• Chronic Obstructive Pulmonary Disease (COPD)
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus (SLE)
• Safety And Adverse Events
• Efficacy And Clinical Trial Outcomes
• Future Directions For Development
• 6.7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Sub-Segmentation Of Alternative Pathway Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• C3 Inhibitors
• Factor B Inhibitors
• Factor D Inhibitors
• Targeting Complement Amplification
• Combination Therapies And Dual Inhibition
• Efficacy And Safety In Clinical Trials
• 6.8. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Sub-Segmentation Of Hematopoietic Stem Cell Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous HSCT vs. Allogeneic HSCT
• Pre-Transplant Conditioning Therapies:
• Post-Transplant Immunosuppressive Therapies
• Stem Cell Sources
• Indications
• Complications
• Recent Advancements
• 6.9. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Sub-Segmentation Of Other Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressive Therapy
• Supportive Care
• Anticoagulation Therapy
• Gene Therapy

7. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Regional And Country Analysis

• 7.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 8.1. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 9.1. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview
• 9.2. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 10.1. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 11.1. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview
• 11.2. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 12.1. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 13.1. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 14.1. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview
• 14.2. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 15.1. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview
• 15.2. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 16.1. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 17.1. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 18.1. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 19.1. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 20.1. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 21.1. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview
• 21.2. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 22.1. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 23.1. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview
• 23.2. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 24.1. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview
• 24.2. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 25.1. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview
• 25.2. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 26.1. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview
• 26.2. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 27.1. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 28.1. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview
• 28.2. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

• 29.1. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview
• 29.2. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation By Market Availability, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Competitive Landscape And Company Profiles

• 30.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Competitive Landscape
• 30.2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis

31. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Other Major And Innovative Companies

• 31.1. Regeneron Pharmaceuticals
• 31.2. Cleveland Clinic Foundation
• 31.3. Johns Hopkins Medicine
• 31.4. Memorial Sloan Kettering Cancer Center
• 31.5. Stanford Health Care
• 31.6. University of California San Francisco (UCSF) Health
• 31.7. Emory Healthcare
• 31.8. Cedars-Sinai Medical Center
• 31.9. Duke University Health System
• 31.10. Mount Sinai Health System
• 31.11. Dana-Farber Cancer Institute
• 31.12. Swedish Orphan Biovitrum
• 31.13. Alnylam Pharmaceuticals
• 31.14. BioCryst Pharmaceuticals
• 31.15. Apellis Pharmaceuticals

32. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

34. Recent Developments In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

35. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34921_Paroxysmal_Nocturnal_Hemoglobinuria_PNH_Treatment_GMR_2025